Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders

Lobe Sciences Ltd. ("Lobe" or the "Company") (OTCQB: LOBEF) (CSE: LOBE), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC ("Clearway"), a wholly owned subsidiary of Sancilio & Company ("Sancilio"), a pharmaceutical services company focused on value creation strategies, are pleased to announce a change in control of the Company and several enhancements to its ongoing growth strategy.

BusinesswireMay 21 09:54 ET

Lobe Sciences Announces Change of Control | CSE:LOBE, OTCQB:LOBEF

Proactive InvestorsMay 21 06:32 ET

Lobe Sciences Provides Company Review of 2023

Stockhouse Jan 8 08:15 ET

Lobe Sciences Provides Update on L-130 Clinical Program

Stockhouse Dec 7, 2023 07:00 ET

Lobe Sciences Provides Update on L-130 Oral Psilocin Compound

Biopharmaceutical company Lobe Sciences Ltd. (LOBE.CSE), on Tuesday announced its lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-mon

MT NewswiresDec 5, 2023 08:37 ET

Lobe Sciences Appoints CFO

Lobe Sciences Ltd. (LOBE.CSE) said Monday that it has named Mathew Lee chief financial officer of the company. Lee currently serves as president of Manning Lee Management Ltd., a management consulting

MT NewswiresSep 18, 2023 13:46 ET